Home › Research › Topics › neurofilament
neurofilament
699 studies tagged neurofilament, dated 1989-01-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival 2026-11-01
- Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study 2026-11-01
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease 2026-10-30
Studies
699 studies carry this tag.
Date range
1989 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 123
- Journal of Alzheimer's disease : JAD 53
- Alzheimer's & dementia (Amsterdam, Netherlands) 46
- Alzheimer's research & therapy 36
- medRxiv 29
196 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
As the most prevalent form of dementia, Alzheimer's disease (AD) represents a major public health challenge.
-
HT was associated with increased CSF α-klotho levels.
-
Plasma p-tau217 was associated with concurrent Aβ in most cortical regions and tau in temporo-parietal cortices.
-
Sixty-nine HC, 13 preclinical AD, 38 AD-MCI, 44 AD-D, and 79 non-AD CI participants were included.
-
Repetitive Head Impacts (RHI) in boxing may increase the risk for neuronal damage.
-
77/100
Plasma NfL and GFAP were associated with vascular brain damage and differed across states (VCI > vascular CU > non-vascular CI > non-vascular CU).
-
In the multivariable linear regression models, a doubling of serum molybdenum level was associated with 9.4% higher Aβ42/40 ratio (95% CI: 0.8, 18.6%; p = 0.03), and a doubling of serum cobalt level with 17.5% higher p-tau181 level (95% CI: 3.1, 33.8%; p = 0.02).
-
We included 400 middle-aged CU participants, of whom 135 (33.8%) were CSF Aβ-positive.
-
The study included 57 patients (54% female, mean age 67 years), of whom 41 met AD diagnostic criteria.
-
Genetic investigations and associations with plasma biomarkers of dementia with Lewy bodies (DLB) in East Asian populations are lacking.
-
Plasma p-tau217 was accurate for discriminating between Core1+ and Core1- patients (area under the curve = 0.92) with an optimal cut-off value of 0.274 pg/mL, revealing good accuracy (86.29%), positive predictive value (PPV; 88.18%), and negative predictive value (NPV; 83.09%).
-
PF and BF were significantly associated with increased likelihoods of dementia, Alzheimer's disease (AD), vascular dementia (VaD), and MCI.
-
Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, cardiovascular disease (CVD), and amyloid- and tau-PET-positive status demonstrated higher p-tau217.
-
We introduce a special issue of the Journal of Neuropsychology dedicated to a recent paradigm shift in Alzheimer's disease diagnosis.
-
In this study, we developed a newly designed μPAD for CL immunoassays, leveraging smartphone-based image capture, valve-regulated reaction process, and app-driven result analysis to enable fully automated detection.
-
Compared to non-carriers, APOE ε4 carriers had lower Aβ42/Aβ40 and greater longitudinal increases in p-tau181 and GFAP; in contrast, the AD-PRS (excluding the APOE region) was associated with greater declines in Aβ42/Aβ40 among APOE ε4 non-carriers.
-
Accurate staging of Alzheimer's disease (AD) pathology is crucial for therapeutic trials and prognosis, but existing fluid biomarkers lack specificity, especially for assessing tau deposition severity, in amyloid-beta (Aβ)-positive patients.
-
In summary, specific biomarkers for AD-related pathologies allow accurate clinical diagnosis of AD based on pathobiological parameters.
-
Alzheimer's disease (AD) is a neurodegenerative disorder characterised by amyloid-β (Aβ), tau hyperphosphorylation and neurodegeneration.
-
Dementia blood biomarkers are becoming increasingly important.
-
Blood phosphorylated (p)-tau 181 and p-tau 217 have been proposed as accurate biomarkers of Alzheimer's disease (AD) pathology.
-
We found that kidney function seems to be associated with AD blood biomarker concentrations.
-
50/100
ALS plasma showed elevation of the established biomarkers, neurofilament light chain (NEFL) and neurofilament heavy chain (NEFH).
-
63/100
NfL demonstrated fair to excellent accuracy in differentiating non-ACS from CU groups (area under the curve [AUC], 0.79 to 0.94). p-tau217 had the highest accuracy for identifying Aβ (AUC 0.94) and tau positron emission tomography status (AUC 0.91).
-
Plasma p-tau217 showed larger fold-changes and better accuracy for detecting AD pathology in symptomatic individuals, with greater cross-platform agreement than other p-tau variants.
-
Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease.
-
This scientific commentary refers to ‘A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests’ by Warmenhoven et al. (https://doi.org/10.1093/brain/awae346) and ‘Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison’ by Pilotto et al. (https://doi.org/10.1093/brain/awae368).
-
66/100
Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology.
-
On NULISA, phosphorylated tau (p-tau217, p-tau231, and p-tau181), glial fibrillary acidic protein (GFAP), and microtubule-associated protein tau (MAPT-tau) showed the top significant association with amyloid beta (Aβ) positron emission tomography (PET) status, followed by the neuroinflammation markers C-C motif ligand 2 (CCL2), chitotriosidase 1 (CHIT1) and interleukin-8 (CXCL8), and the synaptic marker neurogranin (NRGN).
-
Plasma p-tau217 and p-tau217/Aβ1-42 are effective diagnostic tools.
-
The novel IP-MS assay measuring the Aβ42/40 ratio demonstrated an AUC of 0.82 for differentiating AD from control subjects.
-
Higher plasma p-tau181 level was associated with worse memory, executive functioning, and language abilities, and greater informant-reported SCD.
-
43/100
Cerebrospinal fluid (CSF) biomarkers are currently the only clinically validated biofluid diagnostic test for Alzheimer's Disease (AD) available in Australia.
-
HIGHLIGHTS: Different plasma phosphorylated tau (p-tau) species reflect different pathological processes of Alzheimer's disease (AD), with p-tau231 showing the greatest association with the earliest increases in brain amyloid beta (Aβ) accumulation, while p-tau217 shows greater association with both brain Aβ and early tau pathology, and other p-tau and tau fragment species show greater association with later stages of brain tau pathology.
-
55/100
Besides age and estimated glomerular filtration rate (eGFR), significant associations were found between plasma biomarkers and clusters related to hemoglobin, red blood cell distribution, and inflammation.
-
Heritability estimates were 16% for Aβ42/40, 42% for NfL, and 60% for GFAP.
-
p-Tau217 levels were highest in patients with Alzheimer's disease (AD) dementia, whereas NfL levels were highest in patients with frontotemporal dementia (FTD).
-
61/100
Aβ-independent factors included hemoglobin and estimated glomerular filtration rate (eGFR) for p-tau217 and hemoglobin, eGFR, and triiodothyronine (T3) for GFAP and NfL.
-
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment.
-
Plasma phosphorylated Tau 181 (pTau181) and CSF chitinase-3-like protein 1 (YKL-40) increased following semorinemab treatment in both studies.
-
Plasma biomarkers represent promising tools for the screening and diagnosis of patients with neurodegenerative conditions.
-
Early imaging-based detection of acute ischemic stroke (AIS) has improved in the era of reperfusion therapy.
-
SAA+ individuals had faster cognitive decline than SAA-, notably in mild cognitive impairment, and presented with earlier symptom onset.
-
This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes.
-
Neurodegenerative dementias and related diseases, such as Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease have no fundamental cure yet.
-
Our results demonstrate the feasibility and potential of immunoassay-based multiplexing to provide a comprehensive view of AD-associated proteomic changes, consistent with the recently revised biological and diagnostic framework.
-
All measured CSF complement proteins were increased in AD versus CU subjects, with C4a displaying the most robust increase.
-
A total of 337 participants were included: 136 ND, 77 PPD, and 124 Controls.
-
Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for advancing the diagnostics of Alzheimer's disease.
-
There was a direct and indirect bidirectional effect through the glial fibrillary acidic protein of WMH on phosphorylated tau 217 concentration, which was associated with neurofilament light chain concentration in the entire sample.
From across this tag
9 of the 697 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Blood biomarkers of Alzheimer's disease: Balancing clinical relevance with improved accessibility and sustainability
- Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia
- The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease
- Crosswalk study on blood collection-tube types for Alzheimer's disease biomarkers
- Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum
- Why Inclusion Matters for Alzheimer's Disease Biomarker Discovery in Plasma
- SIMOA Diagnostics on Alzheimer's Disease and Frontotemporal Dementia
- Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases
- A Blood Screening Test for Dementia with Lewy Bodies for Primary Care